Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 4/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.49 |
| ▸ | CD274 | Q9NZQ7 | 7/20 | 0.43 |
| ▸ | PDCD1 | Q15116 | 6/20 | 0.43 |
| ▸ | DRD4 | P21917 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 3/20 | 0.40 |
| ▸ | CCR3 | P51677 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 2/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4475332 | 0.88 | ADRB2 (0.43) | ADRB2CHRM3CD274PDCD1HTR7 | |
| SCHEMBL4471205 | 0.86 | CCR3 (0.46) | ADRB2CHRM3DRD4DRD2CCR3 | |
| SCHEMBL264728 | 0.86 | CHRM3 (0.63) | ADRB2CHRM3 | |
| SCHEMBL4487280 | 0.83 | CHRM3 (0.47) | ADRB2CHRM3DRD4DRD2CCR3 | |
| SCHEMBL4483079 | 0.82 | CHRM3 (0.44) | ADRB2CHRM3DRD2HTR7HTR1A | |
| SCHEMBL4491995 | 0.82 | CHRM2 (0.41) | ADRB2CHRM3CD274PDCD1DRD2 | |
| SCHEMBL4494455 | 0.82 | CHRM2 (0.43) | ADRB2CHRM3DRD2 | |
| SCHEMBL4484438 | 0.82 | CHRM3 (0.43) | ADRB2CHRM3DRD2 | |
| SCHEMBL4493960 | 0.82 | CHRM2 (0.42) | ADRB2CHRM3CD274PDCD1CCR3 | |
| SCHEMBL4475337 | 0.80 | CHRM3 (0.45) | ADRB2CHRM3CD274PDCD1HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7632847-B2 | Bronchodilators; treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects, such as dry-mouth and constipation; e.g. biphenyl-2-ylcarbamic acid 1-(2-(3-[3-(4-hydroxybenzylamino)propionylamino]benzoylamino)ethyl)piperidin-4-yl ester | THERAVANCE, INC. (US) | 2009-12-15 | — | — | US | disclosed |